CytomX Therapeutics CTMX Varseta-M — Total External Costs

Similar metrics at other companies

SLSTotal costs & expenses

$9.25M+52.6%

BHVNTotal costs & expenses

$130.43M-41.1%

ARVNARV-393 — Program-specific external expense

$3.7M+42.3%

ARVNARV-102 — Program-specific external expense

$5.5M-15.4%

JANXTotal costs & expenses

$37.95M+8.7%

AGIOTotal costs & expenses

$130.77M+13.4%

Questions, answered.

What is CytomX Therapeutics's varseta-m — total external costs?

CytomX Therapeutics (CTMX) reported varseta-m — total external costs of $6.08M in Q4 2025.

How has CytomX Therapeutics's varseta-m — total external costs changed year-over-year?

CytomX Therapeutics's varseta-m — total external costs increased by 36.2% year-over-year, from $4.46M to $6.08M.

What does varseta-m — total external costs mean?

This metric represents the aggregate third-party expenditures directly attributable to the development and clinical advancement of the Varseta-M program. It encompasses costs such as contract research organization fees, clinical trial site expenses, and outsourced manufacturing services required to support the program's lifecycle. Monitoring these costs provides insight into the capital intensity and operational burn rate associated with specific pipeline assets.